Treating Blindness with Targeted Digital Vision
A game-changing, active digital solution for patients with blinding macular diseases — where no viable treatment currently exists.
About Glaive Medical Optics
Glaive Medical Optics is at the forefront of innovation in ophthalmology, developing groundbreaking technology designed to restore vision for patients affected by blinding macular diseases. As a pioneer in lens implant advancement, Glaive is creating a first-of-its-kind solution that offers a transformative approach to treating vision loss — providing new hope for patients who currently have none. We are dedicated to changing lives through cutting-edge science and a commitment to restoring sight for those who need it most.
Vision Loss from AMD Impacts Millions
Why Now?
Technology Has Arrived
Miniaturization and performance capabilities have only recently reached the targets required for a viable intraocular digital device.
Current Technologies Are Not Solving the Problem
Existing solutions are bulky, static, or impractical concepts that cannot scale to real-world clinical use.
Unique Cross-Industry Expertise
The Glaive team brings rare expertise from inside and outside of ophthalmology, combining surgical, engineering, and commercial depth.
Massive IP Potential
Adjacent applications of Glaive's core technology represent a market opportunity orders of magnitude larger than sight restoration alone.
The Team
Eric Bernabei
- 25+ years developing and launching medical device, pharma, genetic diagnostics, and digital health products
- 15+ years in marketing and management at Alcon
- C-suite roles at Peripherex, Avellino, and Palmona
- Board Chairman at Macuject; Exec in Residence at UCSF Innovation Ventures
Dr. Wayne Harvey Woods Jr., Ph.D.
- Electrical engineer with 100+ international patents generating $10B+ in revenue
- 10+ years at MIT Lincoln Laboratory
- 10+ years at IBM leading 5G innovation
Dr. Christopher L. Shelby, M.D.
- Lead eye surgeon at Willis-Knighton Eye Institute performing 4,000+ surgeries annually
- Board certified; member of AAO, ASCRS, and ESCRS
- Accomplished inventor and entrepreneur in eye care technology
- Prior exit to Welch-Allyn (Baxter)
Asher Gottesman
- Experienced investor and exit specialist; led or participated in $500M+ in deals
- Founder of Transcend RC, Asher G, Jiritsu Network, and Concorde Companies
- Advisor to B Generrous, Woven Science, and Noname Ventures
Dr. Alexander J. Melville, Ph.D.
- 7+ years at MIT Lincoln Laboratory
- Led materials breakthroughs at onsemi, a $20B semiconductor development firm
- 40+ published research articles in materials and chemical science
Interested in Investing?
For information about investing, please contact us.